Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2018

View Archived Issues

Searching for a biomarker for microbiome rehabilitation in recurrent C. difficile infections

Apexigen and Yale Cancer Center enter a clinical collaboration

Faron Pharmaceuticals presents biomarker analysis of the phase III INTEREST trial

Luye Pharma initiates phase III trial of LY03005 in China

Ibulief I.V. Injection launched for patent ductus arteriosus in premature infants

Durvalumab shows promising PFS and tumor response rate in phase II DREAM study in mesothelioma

Diamyd Medical receives approval to initiate phase I/II study of Remygen

First participant dosed in phase II study of vosoritide in infants and young children

Arsanis outlicenses monoclonal antibodies targeting Klebsiella pneumoniae

Eisai subsidiary in joint nucleic acid drug discovery research program

BioClin Therapeutics presents first data from FIERCE-21 trial of B-701 plus docetaxel in mUCC

Responses seen with NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma

Trillium initiates phase I trial of TTI-622 in lymphoma or myeloma

[177Lu]3BP-227 begins phase I/II trial in advanced solid tumors expressing NTSR1

FDA awards RMAT designation to Nightstar's NSR-REP1 for choroideremia

FDA confirms regulatory pathway for Resverlogix's apabetalone

Inozyme introduces genetic testing program for two rare calcification disorders

Temple University and Praeventix present 5-HT7 receptor ligands

NeuroVive Pharmaceutical patents protonophores for NAFLD

Researchers create animal model of ileal recurrence of postoperative Crohn's disease

ContraVir initiates clinical development program with CRV-431 for hepatitis B

ALK inhibitors presented by University of Michigan

3D Medicines divulges linifanib prodrugs for cancer

Georgia State University discloses TNF-alpha production inhibitors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...